Related Experiment Video

Updated: Aug 24, 2025

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.8K

Pan-Tissue and -Cancer Analysis of ROR1 and ROR2 Transcript Variants Identify Novel Functional Significance for an

Miya John1, Caroline E Ford1

  • 1Gynaecological Cancer Research Group, Lowy Cancer Research Centre, School of Women's and Children's Health, Faculty of Medicine and Health, University of New South Wales, Cnr High and Botany St., Kensington, Sydney, NSW 2052, Australia.

Biomedicines
|October 27, 2022
PubMed

Insights

ROR1 and ROR2 are key targets in cancer therapy. This study reveals their varied expression patterns and identifies a predominant ROR1 variant lacking cell surface localization, impacting targeted therapy safety.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Receptor tyrosine kinase-like orphan receptor 1 (ROR1) and ROR2 are increasingly recognized as significant druggable targets in translational oncology.
  • Systematic examination of ROR1/2 mRNA and transcript variant expression has been lacking.

Purpose of the Study:

  • To systematically analyze ROR1/2 mRNA and transcript variant expression across diverse human tissues and cancer types.
  • To identify predominant transcript variants and assess their potential for cell surface localization.

Main Methods:

  • Analysis of ROR1/2 transcript variant sequences and predicted signal peptides.
  • Examination of mRNA and transcript variant expression in 34 transcriptomic datasets (33 cancer types, 54 non-diseased tissues).

Main Results:

  • ROR1 has four and ROR2 has eight transcript variants, with expression detected in various non-diseased tissues.
  • Predominant ROR1 expression is from variant ENST00000545203 (lacks signal peptide), not the predicted ENST00000371079.
  • Predominant ROR2 expression is from variant ENST00000375708.

Conclusions:

  • ROR1/2 expression in healthy tissues necessitates careful consideration for targeted therapy safety assessments.
  • Further research into the function and significance of the predominant ROR1 variant (ENST00000545203) is warranted.
Keywords:
ROR1ROR2bioinformatic meta-analysissub-cellular localisationtranscript variants

More Related Videos

Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp111:02

Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1

Published on: May 27, 2016

8.2K
Identification of Alternative Splicing and Polyadenylation in RNA-seq Data08:35

Identification of Alternative Splicing and Polyadenylation in RNA-seq Data

Published on: June 24, 2021

5.7K

Related Concept Videos

RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
56.7K
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
21.6K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.4K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.8K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.3K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.7K